PMID- 35751775
OWN - NLM
STAT- MEDLINE
DCOM- 20220819
LR  - 20221023
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 77
IP  - 3
DP  - 2022 Sep
TI  - Increased levels of insulin-degrading enzyme in patients with type 2 diabetes 
      mellitus.
PG  - 561-565
LID - 10.1007/s12020-022-03123-7 [doi]
AB  - PURPOSE: Decreasing levels of serum insulin-degrading enzyme (IDE) have been 
      associated with an increased risk for Alzheimer s disease (AD) in patients with 
      type 2 diabetes mellitus (T2DM). Research on serum IDE levels in patients with 
      T2DM is sparse and the aim of this study was to explore serum levels of IDE in 
      patients with T2DM. METHOD: Blood serum samples were obtained from a biobank. 
      Samples from subjects with T2DM and without metabolic disease were divided into 
      subgroups; lifestyle treatment (n = 10), oral antidiabetic treatment (n = 17), 
      insulin treatment (n = 20) and metabolically healthy controls (n = 18). Serum 
      levels of IDE were analysed using specific ELISA assays. RESULTS: Serum levels of 
      IDE were elevated in subjects with T2DM compared to metabolically healthy 
      individuals (p = 0.033). No significant differences were detected between 
      treatment subgroups. CONCLUSION: The present study indicates that patients with 
      T2DM have increased serum IDE levels, compared to metabolically healthy 
      individuals. However, for IDE to be clinically useful as a biomarker, its full 
      function and possible use needs to be further elucidated in larger studies 
      showing reproducible outcomes.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Kullenberg, Helena
AU  - Kullenberg H
AUID- ORCID: 0000-0002-0785-7029
AD  - Department of Health Promoting Science, Sophiahemmet University, Stockholm, 
      Sweden. Helena.Kullenberg@shh.se.
FAU - Rossen, Jenny
AU  - Rossen J
AD  - Department of Health Promoting Science, Sophiahemmet University, Stockholm, 
      Sweden.
FAU - Johansson, Unn-Britt
AU  - Johansson UB
AD  - Department of Health Promoting Science, Sophiahemmet University, Stockholm, 
      Sweden.
AD  - Department of Clinical Science and Education, Karolinska Institutet, 
      Sodersjukhuset, Stockholm, Sweden.
FAU - Hagstromer, Maria
AU  - Hagstromer M
AD  - Department of Health Promoting Science, Sophiahemmet University, Stockholm, 
      Sweden.
AD  - Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, 
      Karolinska Institutet, Stockholm, Sweden.
AD  - Academic Primary Health Care Centre, Region Stockholm, Stockholm, Sweden.
FAU - Nystrom, Thomas
AU  - Nystrom T
AD  - Department of Clinical Science and Education, Karolinska Institutet, 
      Sodersjukhuset, Stockholm, Sweden.
FAU - Kumlin, Maria
AU  - Kumlin M
AD  - Department of Health Promoting Science, Sophiahemmet University, Stockholm, 
      Sweden.
FAU - Svedberg, Marie M
AU  - Svedberg MM
AD  - Department of Health Promoting Science, Sophiahemmet University, Stockholm, 
      Sweden.
LA  - eng
PT  - Journal Article
DEP - 20220625
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - EC 3.4.24.56 (Insulysin)
SB  - IM
MH  - *Alzheimer Disease/complications
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Humans
MH  - *Insulysin/blood
OTO - NOTNLM
OT  - Insulin resistance
OT  - Insulin-degrading enzyme
OT  - Type 2 diabetes mellitus
EDAT- 2022/06/26 06:00
MHDA- 2022/08/20 06:00
CRDT- 2022/06/25 11:21
PHST- 2022/06/14 00:00 [received]
PHST- 2022/06/18 00:00 [accepted]
PHST- 2022/06/26 06:00 [pubmed]
PHST- 2022/08/20 06:00 [medline]
PHST- 2022/06/25 11:21 [entrez]
AID - 10.1007/s12020-022-03123-7 [pii]
AID - 10.1007/s12020-022-03123-7 [doi]
PST - ppublish
SO  - Endocrine. 2022 Sep;77(3):561-565. doi: 10.1007/s12020-022-03123-7. Epub 2022 Jun 
      25.